/
Respiratory
Chronic Rhinosinusitis With Nasal Polyps
11
Pipeline Programs↗
28
Active Trials↗
16
Companies Involved↗
Chronic Rhinosinusitis With Nasal Polyps is an emerging landscape with 11 programs across 16 companies. The most active players are Sanofi, Guangdong Hengrui Pharmaceutical Co., Ltd, Longbio Pharma. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 24
Phase 35
Approved
No programs
Analysis
Modality Breakdown
78%
Small molecule
7 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
55
clinical trials
Completed15 · 27%
Recruiting11 · 20%
Active, not recruiting8 · 15%
Not yet recruiting8 · 15%
Terminated6 · 11%
Unknown status4 · 7%
Other3 · 5%
Clinical Trials
Trial Activity
55 trials
Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps
Recruiting·—·Phase 4·NCT07187583·135 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)